An interventional study of Karisma in Wrinkle, Scar and Laxity; Skin, sponsored by Taumedika s.r.l.. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Taumedika s.r.l. · Not applicable, Interventional, and Treatment
Study to validate the safety and efficacy of the Hyaluronic Acid +Collagen filler 40 patients will undergo through 3 visits one to asses the health and apply the filler one after 4 weeks to check the results one after 16 weeks for the final check and results validation Safety assessed with analysis of the Adverse Events
The patients chosen with facial laxity characteristics, at the first visit will be assessed and will receive the treatment (microinjections) in the cheekbone area, over the lips and in the marionette lines. After 4 weeks the first visit will assess the change of the tissutal structure with non invasive measurements.
611 studies on the registry are indexed under Cicatrix; 114 are open to participants now.
This study's planned enrollment of 40 is close to the median of 40 across 512 interventional studies indexed under Cicatrix.
Browse Cicatrix studies →This is the only study on the registry with Taumedika s.r.l. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated for face needs with Karisma micro injections
Device: Karisma
Patients treated for face needs with Karisma microinjections
Device: Karisma
Intradermal injection
Also known as: Karisma filler
Safety: no adverse events
test the safety of the device evaluating any potential adverse event
Time frame: 16 weeks
Efficacy: change of wrinkles and scars
test the efficacy of the device measuring the skin surface using GAIS (Global Aesthetic Improvement Scale) scale
Time frame: 16 weeks
Efficacy: change of wrinkles and scars
test the efficacy of the device measuring the skin surface using Facial Volume Loss Scale (FVLS)
Time frame: 16 weeks
Efficacy: change of wrinkles and scars
test the efficacy of the device measuring the skin surface evaluating the face volume
Time frame: 16 weeks
Efficacy: change of wrinkles and scars
test the efficacy of the device measuring the skin surface with skin hydratation measurement
Time frame: 16 weeks
Duration of the efficacy
measure the duration of the treatment
Time frame: 16 weeks
Plan to share: No — Not foreseen
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 33 industry-sponsored interventional studies with no phase under Cicatrix, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's planned 3 months is below that.
Counting every sponsor, half of 206 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Feb 2026 → Nov 2026, primary completion Mar 2026 → Feb 2027 and completion Jun 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.